Lista de obras - Martin Dreyling - Dominio Público Uruguay

2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma

artículo científico publicado en 2009

A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms

artículo científico publicado en 2009

A multiplex MALDI-TOF MS approach facilitates genotyping of DNA from formalin-fixed paraffin-embedded tumour specimens ⬇️

artículo científico publicado el 1 de octubre de 2010

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

artículo científico publicado en 2008

A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse la

artículo científico publicado en 2013

A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas

artículo científico publicado en 2010

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymp

artículo científico publicado en 2016

Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma

artículo científico publicado en 2011

Bendamustine for patients with B cell lymphoid malignancies

artículo científico publicado en 2011

Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia

artículo científico publicado en 2012

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

artículo científico publicado en 2007

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

artículo científico publicado en 2016

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

artículo científico publicado en 2006

Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network

artículo científico publicado en 2014

Current management of follicular lymphomas

artículo científico publicado en 2006

Current management of mantle cell lymphoma

artículo científico publicado en 2007

Current status and perspective of antibody therapy in follicular lymphoma.

artículo científico publicado en 2006

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

artículo científico publicado en 2004

Follicular dendritic cells in follicular lymphoma and types of non-Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcome.

artículo científico publicado en 2011

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

artículo científico publicado en 2005

Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

artículo científico publicado en 2017

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).

artículo científico publicado en 2007

High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma

artículo científico publicado en 2015

Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network

artículo científico publicado en 2005

How to treat old MCL patients: one size fits it all?

artículo científico publicado en 2014

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

artículo científico publicado en 2005

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

artículo científico publicado en 2007

Impact of age on genetics and treatment efficacy in follicular lymphoma.

artículo científico publicado en 2018

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

artículo científico publicado en 2015

Investigational strategies in autologous stem cell transplantation for follicular lymphoma

artículo científico publicado en 2006

Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network

artículo científico publicado en 2009

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

artículo científico publicado en 2007

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

artículo científico publicado en 2014

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

artículo científico publicado en 2015

Management of Mantle Cell Lymphoma: Key Challenges and Next Steps ⬇️

artículo científico publicado el 1 de octubre de 2010

Mantle cell lymphoma: Therapeutic strategies are different from CLL ⬇️

artículo científico publicado el 1 de junio de 2003

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era ⬇️

artículo científico publicado el 12 de octubre de 2010

Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop

artículo científico publicado en 2010

Mantle cell lymphoma: state-of-the-art management and future perspective

artículo científico publicado en 2009

Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.

artículo científico publicado en 2008

Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study

artículo científico publicado en 2015

Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Stu

artículo científico publicado en 2004

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

artículo científico publicado en 2009

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group

artículo científico publicado en 2004

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

artículo científico publicado en 2014

Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma

artículo científico publicado en 2016

Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas

artículo científico publicado en 2012

Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8

artículo científico publicado en 2011

Postibrutinib outcomes in patients with mantle cell lymphoma

artículo científico publicado en 2016

Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation

artículo científico publicado en 2013

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network

artículo científico publicado en 2016

Proteome- and microarray-based expression analysis of lymphoma cell lines identifies a p53-centered cluster of differentially expressed proteins in mantle cell and follicular lymphoma.

artículo científico publicado en 2007

Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.

artículo científico publicado en 2005

Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.

artículo científico publicado en 2006

Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease

artículo científico publicado en 2006

Rituximab plus chemotherapy in follicular and mantle cell lymphomas

artículo científico publicado en 2003

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.

artículo científico publicado en 2016

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

artículo científico publicado en 2010

Successful salvage treatment of chronic refractory immune thrombocytopenia using a simplified method to generate vincristine-loaded platelets.

artículo científico publicado en 2008

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

artículo científico publicado en 2013

The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date

artículo científico publicado en 2016

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

artículo científico publicado en 2004

The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity

artículo científico publicado en 2014

The role of fludarabine in the treatment of follicular and mantle cell lymphoma

artículo científico publicado en 2004

The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?

artículo científico publicado en 2016

Transplantation strategies for patients with follicular lymphoma

artículo científico publicado en 2005

Treatment strategies in follicular lymphomas: current status and future perspectives

artículo científico publicado en 2005

Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group

artículo científico publicado en 2007

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network

artículo científico

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network

artículo científico publicado en 2012

Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network

article

Lista de obras de Martin Dreyling

2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma

A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms

A multiplex MALDI-TOF MS approach facilitates genotyping of DNA from formalin-fixed paraffin-embedded tumour specimens ⬇️

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse la

A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymp

Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma

Bendamustine for patients with B cell lymphoid malignancies

Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network

Current management of follicular lymphomas

Current management of mantle cell lymphoma

Current status and perspective of antibody therapy in follicular lymphoma.

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

Follicular dendritic cells in follicular lymphoma and types of non-Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcome.

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).

High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma

Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network

How to treat old MCL patients: one size fits it all?

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

Impact of age on genetics and treatment efficacy in follicular lymphoma.

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Investigational strategies in autologous stem cell transplantation for follicular lymphoma

Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

Management of Mantle Cell Lymphoma: Key Challenges and Next Steps ⬇️

Mantle cell lymphoma: Therapeutic strategies are different from CLL ⬇️

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era ⬇️

Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop

Mantle cell lymphoma: state-of-the-art management and future perspective

Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.

Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study

Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Stu

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma

Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas

Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8

Postibrutinib outcomes in patients with mantle cell lymphoma

Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network

Proteome- and microarray-based expression analysis of lymphoma cell lines identifies a p53-centered cluster of differentially expressed proteins in mantle cell and follicular lymphoma.

Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.

Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.

Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease

Rituximab plus chemotherapy in follicular and mantle cell lymphomas

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

Successful salvage treatment of chronic refractory immune thrombocytopenia using a simplified method to generate vincristine-loaded platelets.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity

The role of fludarabine in the treatment of follicular and mantle cell lymphoma

The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?

Transplantation strategies for patients with follicular lymphoma

Treatment strategies in follicular lymphomas: current status and future perspectives

Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network

Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network